|
Patent landscape, scope, and claims: |
United States Drug Patent 7,119,202: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 7,119,202, focusing on its patent claims, scope, and the surrounding patent landscape. The patent, titled "Therapeutic Uses of Interleukin-1 Receptor Antagonists," was granted to Amgen Inc. on October 10, 2006. It pertains to the treatment of inflammatory diseases using specific interleukin-1 receptor antagonists.
What Are the Core Claims of Patent 7,119,202?
Patent 7,119,202 is directed towards methods of treating inflammatory diseases by administering a therapeutically effective amount of an interleukin-1 receptor antagonist. The primary claims focus on the use of such antagonists, rather than the molecules themselves.
-
Claim 1: A method for treating an inflammatory disease in a subject, comprising administering to the subject a therapeutically effective amount of an interleukin-1 receptor antagonist. This claim broadly covers the therapeutic application.
-
Claim 2: The method of claim 1, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, adult rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis, and chronic obstructive pulmonary disease. This claim specifies a list of treatable conditions.
-
Claim 3: The method of claim 1, wherein the interleukin-1 receptor antagonist is a protein. This claim defines the nature of the antagonist.
-
Claim 4: The method of claim 3, wherein the protein is a soluble receptor molecule or a fragment thereof. This specifies a type of protein antagonist.
-
Claim 5: The method of claim 4, wherein the soluble receptor molecule is an interleukin-1 receptor molecule or a fragment thereof. This further refines the type of soluble receptor.
-
Claim 6: The method of claim 5, wherein the interleukin-1 receptor molecule is an IL-1RI or a fragment thereof. This specifies the particular interleukin-1 receptor.
-
Claim 7: The method of claim 6, wherein the fragment is capable of binding to IL-1. This focuses on the functional aspect of the fragment.
-
Claim 8: The method of claim 1, wherein the interleukin-1 receptor antagonist is an antibody. This introduces another type of antagonist.
-
Claim 9: The method of claim 8, wherein the antibody is a monoclonal antibody. This specifies a subtype of antibody.
-
Claim 10: The method of claim 9, wherein the monoclonal antibody is capable of binding to an interleukin-1 receptor. This defines the antibody's target.
-
Claim 11: The method of claim 1, wherein the interleukin-1 receptor antagonist is an engineered protein. This encompasses protein-based antagonists that are not naturally occurring.
-
Claim 12: The method of claim 1, wherein the therapeutically effective amount is from about 0.01 mg/kg to about 10 mg/kg. This establishes a dosage range for the antagonist.
-
Claim 13: The method of claim 1, wherein the therapeutically effective amount is from about 0.1 mg/kg to about 5 mg/kg. This provides a narrower dosage range.
-
Claim 14: The method of claim 1, wherein the therapeutically effective amount is from about 1 mg/kg to about 3 mg/kg. This offers an even more specific dosage range.
-
Claim 15: The method of claim 1, wherein the interleukin-1 receptor antagonist is provided in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. This addresses the formulation aspect.
-
Claim 16: The method of claim 15, wherein the pharmaceutical composition is a liquid formulation. This specifies a liquid formulation.
-
Claim 17: The method of claim 15, wherein the pharmaceutical composition is a lyophilized formulation. This specifies a lyophilized formulation.
-
Claim 18: The method of claim 1, wherein the subject is a human. This specifies the target subject.
-
Claim 19: The method of claim 18, wherein the inflammatory disease is rheumatoid arthritis. This reiterates a specific disease for a human subject.
-
Claim 20: The method of claim 1, further comprising administering to the subject an anti-inflammatory drug. This allows for combination therapy.
-
Claim 21: The method of claim 20, wherein the anti-inflammatory drug is a non-steroidal anti-inflammatory drug (NSAID). This specifies the type of co-administered drug.
-
Claim 22: The method of claim 21, wherein the NSAID is selected from the group consisting of ibuprofen, naproxen, and diclofenac. This lists specific NSAIDs.
-
Claim 23: The method of claim 20, wherein the anti-inflammatory drug is a corticosteroid. This specifies another type of co-administered drug.
What Is the Scope of Patent 7,119,202?
The scope of patent 7,119,202 is defined by its method-of-use claims. It protects the application of specific types of interleukin-1 receptor antagonists for treating certain inflammatory conditions. This means that while the patent may not claim the antagonist molecule itself (if it was previously known or patented), it claims its use for a particular therapeutic purpose.
Key aspects of its scope include:
- Target Diseases: The patent specifically lists and covers the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, adult rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis, and chronic obstructive pulmonary disease.
- Therapeutic Agents: The protected agents are broadly defined as "interleukin-1 receptor antagonists," with further specifications including proteins, soluble receptor molecules (or fragments), antibodies (including monoclonal antibodies), and engineered proteins.
- Dosage Ranges: Specific therapeutic dosage ranges are defined, providing a concrete parameter for infringement.
- Formulations: Pharmaceutical compositions, including liquid and lyophilized forms, are covered.
- Combination Therapy: The patent also claims methods that involve co-administering the interleukin-1 receptor antagonist with other anti-inflammatory drugs, such as NSAIDs (ibuprofen, naproxen, diclofenac) and corticosteroids.
- Subject: The claims are directed towards treating a "subject," with specific mention of humans.
The patent's strength lies in its broad claims covering the method of treatment using a class of compounds, even if specific compounds within that class might be covered by other patents. This type of claim can be critical for protecting a drug's market exclusivity for its approved indications.
What Is the Patent Landscape for Interleukin-1 Receptor Antagonists?
The patent landscape surrounding interleukin-1 receptor antagonists is extensive and complex, reflecting the significant therapeutic potential of targeting the IL-1 pathway in inflammatory diseases. Patent 7,119,202 is part of a broader ecosystem of intellectual property protecting various aspects of IL-1 inhibition.
Key Players and Their Intellectual Property
- Amgen Inc.: As the assignee of patent 7,119,202, Amgen is a major player. Their flagship IL-1 inhibitor, Anakinra (Kineret), is a recombinant human interleukin-1 receptor antagonist protein. Patent 7,119,202 likely supports the marketing of Anakinra for its approved indications, such as rheumatoid arthritis. Amgen has a portfolio of patents covering Anakinra's production, formulation, and therapeutic uses [1].
- Regeneron Pharmaceuticals and Sanofi: These companies jointly developed Sarilumab (Kevzara), a monoclonal antibody that blocks the IL-1 receptor. Their patent strategy would involve protection of the antibody molecule itself, its manufacturing, and its therapeutic applications in conditions like rheumatoid arthritis [2].
- Other Biologics Developers: Numerous other companies have developed or are developing biologic agents targeting IL-1, including antibodies against IL-1 beta itself (e.g., Canakinumab, Rilonacept), which indirectly affects IL-1 receptor signaling. These companies hold patents covering their specific antibody sequences, therapeutic uses, and manufacturing processes.
- Small Molecule Inhibitors: While patent 7,119,202 primarily focuses on protein and antibody antagonists, the IL-1 pathway can also be targeted by small molecules. Research in this area has led to patents protecting novel small molecule inhibitors of IL-1 signaling pathways, such as those inhibiting downstream kinases.
Types of Patents in the Landscape
The patent landscape for IL-1 receptor antagonists includes:
- Composition of Matter Patents: These patents claim the novel molecules themselves, such as specific antibody sequences or engineered protein structures. These are generally the strongest forms of patent protection.
- Method of Use Patents: Similar to patent 7,119,202, these claims protect the application of known or novel compounds for specific therapeutic indications. This is crucial for extending patent life or protecting new uses of existing drugs.
- Formulation Patents: These patents cover specific formulations of drugs (e.g., stable liquid formulations, sustained-release compositions) that can improve efficacy, patient compliance, or manufacturing.
- Manufacturing Process Patents: Claims related to novel or improved methods for producing the therapeutic agent.
- Polymorph and Salt Patents: For small molecules, patents on specific crystalline forms (polymorphs) or salts can provide additional layers of protection.
Key Therapeutic Areas Covered
The primary therapeutic areas protected by patents in this landscape are autoimmune and inflammatory diseases:
- Rheumatoid Arthritis (RA): This is a major focus, with many IL-1 inhibitors approved or in development for RA.
- Juvenile Idiopathic Arthritis (JIA): A significant indication for IL-1 pathway modulation.
- Gout and Pseudogout: Inflammatory conditions where IL-1 plays a role.
- Cardiovascular Disease: Specifically, targeting inflammation associated with atherosclerosis.
- Auto-inflammatory Syndromes: Such as Familial Mediterranean Fever (FMF) and deficiency of the interleukin-1 receptor antagonist (DIRA).
- Chronic Obstructive Pulmonary Disease (COPD): As indicated in patent 7,119,202.
Patent Expirations and Generic Competition
The expiration of foundational patents for early IL-1 inhibitors has opened avenues for generic competition. However, companies often strategically file new patents for improved formulations, new indications, or combination therapies to extend market exclusivity. For instance, patent 7,119,202, a method-of-use patent, could extend protection for specific applications of Anakinra beyond the expiration of patents covering the molecule itself.
The complexity of the landscape necessitates thorough freedom-to-operate (FTO) analyses for any new entrant or development involving IL-1 pathway modulation.
What Are the Potential Infringement Risks Associated with Patent 7,119,202?
Potential infringement of United States Patent 7,119,202 arises from conducting the claimed methods without authorization from the patent holder, Amgen Inc. The broad nature of the method-of-use claims means that a wide range of activities could potentially fall under its purview.
Key Areas of Infringement Risk
-
Therapeutic Use for Specified Diseases:
- Administering any interleukin-1 receptor antagonist (protein, antibody, engineered protein) to a subject diagnosed with rheumatoid arthritis, juvenile rheumatoid arthritis, adult rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis, or chronic obstructive pulmonary disease.
- This risk is particularly high if the antagonist is one that binds to the IL-1 receptor or an engineered protein designed to block IL-1 signaling.
-
Specific Antagonist Types:
- Protein Antagonists: Using protein-based IL-1 receptor antagonists. This includes naturally occurring soluble receptors, fragments thereof, or engineered proteins.
- Antibody Antagonists: Using monoclonal antibodies capable of binding to an interleukin-1 receptor.
-
Dosage and Formulation:
- Administering the antagonist within the claimed dosage ranges (0.01 mg/kg to 10 mg/kg, or the narrower ranges of 0.1 mg/kg to 5 mg/kg, or 1 mg/kg to 3 mg/kg) for the treatment of the listed diseases.
- Using pharmaceutical compositions in liquid or lyophilized formulations for therapeutic administration.
-
Combination Therapy:
- Co-administering an IL-1 receptor antagonist with a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen, naproxen, or diclofenac, or with a corticosteroid, for the treatment of the specified inflammatory diseases. This is a distinct method claim and an independent basis for infringement.
-
Target Subject:
- Performing any of the above methods on human subjects.
Factors Influencing Infringement Determination
- Identification of the Antagonist: Determining whether a competitor's drug functions as an interleukin-1 receptor antagonist and engages the IL-1 receptor. This may involve detailed biochemical and biological assays.
- Disease Indication: Confirming that the competitor's drug is being marketed, promoted, or used for one of the specific inflammatory diseases listed in the patent. Off-label use by physicians could also constitute infringement if there is evidence of inducement or encouragement by the manufacturer.
- Dosage and Formulation: Verifying if the competitor's product uses dosages and formulations that fall within the patent's claims.
- Combination Therapy: Establishing whether the competitor's drug is promoted or used in conjunction with NSAIDs or corticosteroids for the patented indications.
- Patent Validity and Enforceability: The strength of the patent itself is a factor. Infringement can only occur if the patent is valid and enforceable. Competitors may challenge the patent's validity based on prior art or other legal grounds.
Mitigation Strategies for Potential Infringement
Companies developing or marketing drugs that interact with the IL-1 pathway must conduct thorough freedom-to-operate (FTO) analyses. This includes:
- Patent Searching and Analysis: Comprehensive searches of the patent landscape to identify relevant patents, including patent 7,119,202 and its continuations or related patents.
- Legal Opinion: Obtaining a legal opinion from patent counsel regarding non-infringement or invalidity.
- Design-Around Strategies: Modifying the proposed drug, its indication, dosage, formulation, or combination therapy to avoid the specific claims of patent 7,119,202. For example, targeting a different pathway or a downstream mediator of IL-1 signaling, or focusing on diseases not listed in the patent.
- Licensing or Cross-Licensing: Negotiating a license with Amgen Inc. to use the patented methods.
Given that patent 7,119,202 is a method-of-use patent with specific disease indications and dosage parameters, the risk of infringement is directly tied to a competitor's commercialization activities and the specific therapeutic profile of their product.
Key Takeaways
- United States Patent 7,119,202 protects methods of treating specific inflammatory diseases using interleukin-1 receptor antagonists.
- The patent covers a range of antagonist types, including proteins, antibodies, and engineered proteins, and specifies target diseases such as rheumatoid arthritis, COPD, and others.
- Key claims also define therapeutic dosage ranges and cover combination therapies with NSAIDs and corticosteroids.
- The patent landscape for IL-1 pathway inhibitors is extensive, involving multiple companies and various patent types, including composition of matter, method of use, and formulation patents.
- Potential infringement risks lie in the unauthorized commercialization or use of IL-1 receptor antagonists for the patented indications, within specified dosages, or in combination therapies.
- Thorough freedom-to-operate analyses are critical for companies developing drugs targeting the IL-1 pathway to mitigate infringement risks.
Frequently Asked Questions
-
Does patent 7,119,202 claim the drug Anakinra itself?
No, patent 7,119,202 is a method-of-use patent. It claims the method of treating specific diseases by administering an interleukin-1 receptor antagonist. While Anakinra is an IL-1 receptor antagonist and would fall under the scope of this patent if used for the claimed indications, the patent itself does not claim the Anakinra molecule as a composition of matter.
-
What are the specific inflammatory diseases covered by patent 7,119,202?
The patent explicitly lists rheumatoid arthritis, juvenile rheumatoid arthritis, adult rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis, and chronic obstructive pulmonary disease.
-
Can a company develop a new antibody that blocks the IL-1 receptor without infringing patent 7,119,202?
Developing a new antibody that blocks the IL-1 receptor requires careful analysis. If this new antibody is used to treat any of the diseases listed in patent 7,119,202, within the specified dosage ranges, or in combination therapies as claimed, it would likely constitute infringement of this method-of-use patent, even if the antibody molecule itself is novel and covered by a separate composition of matter patent.
-
If a drug is used "off-label" for a condition listed in patent 7,119,202, does that constitute infringement?
Off-label use can lead to infringement, particularly if the manufacturer actively induces or encourages such use. While individual physicians prescribing off-label are generally not sued for infringement of method-of-use patents, the patent holder can pursue action against the manufacturer if they can demonstrate that the company's actions facilitated or promoted the infringement of the patented method.
-
How does patent 7,119,202 differ from patents that claim the specific molecule of an IL-1 receptor antagonist?
Composition of matter patents claim the unique chemical structure or biological entity of a drug molecule. Method of use patents, like 7,119,202, claim a specific therapeutic application or process involving a drug or class of drugs. Patent 7,119,202 protects the act of treating certain diseases with IL-1 receptor antagonists, regardless of whether the antagonist molecule itself is novel or patented elsewhere. This type of patent can extend market exclusivity for a drug's approved uses beyond the expiration of its composition of matter patent.
Citations
[1] Amgen Inc. (2006). Therapeutic Uses of Interleukin-1 Receptor Antagonists (U.S. Patent No. 7,119,202). United States Patent and Trademark Office.
[2] Regeneron Pharmaceuticals, Inc. & Sanofi-Aventis U.S. LLC. (2017). Anti-IL-1 Receptor Antibodies and Methods of Use (U.S. Patent No. 9,757,507). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
